# Oral Cladribine in Early Multiple Sclerosis (MS)

> **NCT00725985** · PHASE3 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 617 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Placebo
- **DRUG:** Rebif® new formulation (RNF)

## Key facts

- **NCT ID:** NCT00725985
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-31
- **Primary completion:** 2011-07-31
- **Final completion:** 2012-04-30
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725985, "Oral Cladribine in Early Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00725985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*